BioCentury | Oct 10, 2019
Company News

Management tracks: Galderma taps new leadership from Shire; plus iOmx, BioSpecifics, Poseida, Kedalion, GenSight, Lyra, Verrica and Mizuho

...last week as part of a $10 billion spinout from Nestlé S.A. (SWX:NESN). Cancer company iOmx Therapeutics AG...
...cap pharmaceutical and biotechnology companies. He was a senior analyst at Credit Suisse. Jonathan Block, Associate Editor iOmx Therapeutics AG BioSpecifics...
BioCentury | Oct 4, 2019
Preclinical News

Oct. 3 Preclinical Quick Takes: Funding for NIH hubs; plus a fibroblast inflammasome-metastasis link, iOmx and OSE

...in combination with checkpoint inhibitors for advanced solid cancers. iOmx developing inhibitors of novel checkpoints iOmx Therapeutics AG...
...PD-1 (PDCD1, CD279) - programmed cell death 1; SIK3 - salt-inducible kinase 3 BioCentury Staff NIH OSE Immunotherapeutics S.A. iOmx Therapeutics AG Programmed...
BioCentury | Oct 6, 2017
Financial News

Cullinan raises $150M in series A

...previously co-founded several other MPM cancer start-ups, including Harpoon Therapeutics Inc. (South San Francisco, Calif.), iOmx Therapeutics AG...
BioCentury | Oct 3, 2017
Financial News

Cullinan raises $150M series A round

...previously co-founded several other MPM cancer start-ups, including Harpoon Therapeutics Inc. (South San Francisco, Calif.), iOmx Therapeutics AG...
BioCentury | Sep 27, 2017
Financial News

Sofinnova names Richter managing partner

...Novo Holdings A/S (Hellerup, Denmark). She is also chairman of iOmx Therapeutics AG (Martinsried, Germany). Sofinnova co-led iOmx's...
...last year, marking the VC's entrance into immuno-oncology (see BioCentury, Sept. 26, 2016) . Elizabeth S. Eaton iOmx Therapeutics AG Novo...
BioCentury | May 25, 2017
Finance

Europe’s translational springtime

...Techology ; Francis Crick Institute ; King’s College London ; Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) iOmx Therapeutics AG...
...was cancer play iOmx Therapeutics AG , based on technology from the German Cancer Research Center (DKFZ). iOmx...
...et de la Recherche Médicale (INSERM), Paris, France The Institute of Cancer Research, London, U.K. iOmx Therapeutics AG...
BioCentury | Dec 9, 2016
Emerging Company Profile

Tumor cell checkpoints

...the activity of T cells?” The targets were identified using high throughput siRNA screening technology iOmx...
...iOmx plans to develop mAbs for patients who failed treatment with PD-1/PD-L1 inhibitors. Meier-Ewert said iOmx...
...paper describing iOmx’s technology, is “promising.” The 2015 paper, published in EMBO Molecular Medicine by iOmx’s...
BioCentury | Sep 26, 2016
Finance

Getting into the I-O mix

...After years of sitting on the sidelines, Sofinnova Partners is entering immuno-oncology by backing iOmx Therapeutics AG's €40...
...PD-L1 axis," said Sofinnova's Henrijette Richter, who is iOmx's chairman. "What captured us is that iOmx...
...financing is the fourth-largest German biotech series A since BioCentury started tracking financings in 1994. iOmx's...
BioCentury | Sep 26, 2016
Financial News

iOmx completes venture financing

iOmx Therapeutics AG , Martinsried, Germany Business: Cancer Date completed: 2016-09-22 Type: Venture financing Raised: EUR40 million ($44.6 million) Investors: MPM Capital; Sofinnova Partners; Wellington Partners; Merck Ventures B.V. WIR Staff...
BioCentury | Sep 22, 2016
Financial News

iOmx raises EUR 40M series A round

...Immuno-oncology company iOmx Therapeutics AG (Martinsried, Germany) raised EUR 40 million ($44.6 million) in a series A round...
...preclinical-stage biotech is developing antibodies against checkpoint targets found on tumors rather than immune cells. iOmx...
Items per page:
1 - 10 of 10
BioCentury | Oct 10, 2019
Company News

Management tracks: Galderma taps new leadership from Shire; plus iOmx, BioSpecifics, Poseida, Kedalion, GenSight, Lyra, Verrica and Mizuho

...last week as part of a $10 billion spinout from Nestlé S.A. (SWX:NESN). Cancer company iOmx Therapeutics AG...
...cap pharmaceutical and biotechnology companies. He was a senior analyst at Credit Suisse. Jonathan Block, Associate Editor iOmx Therapeutics AG BioSpecifics...
BioCentury | Oct 4, 2019
Preclinical News

Oct. 3 Preclinical Quick Takes: Funding for NIH hubs; plus a fibroblast inflammasome-metastasis link, iOmx and OSE

...in combination with checkpoint inhibitors for advanced solid cancers. iOmx developing inhibitors of novel checkpoints iOmx Therapeutics AG...
...PD-1 (PDCD1, CD279) - programmed cell death 1; SIK3 - salt-inducible kinase 3 BioCentury Staff NIH OSE Immunotherapeutics S.A. iOmx Therapeutics AG Programmed...
BioCentury | Oct 6, 2017
Financial News

Cullinan raises $150M in series A

...previously co-founded several other MPM cancer start-ups, including Harpoon Therapeutics Inc. (South San Francisco, Calif.), iOmx Therapeutics AG...
BioCentury | Oct 3, 2017
Financial News

Cullinan raises $150M series A round

...previously co-founded several other MPM cancer start-ups, including Harpoon Therapeutics Inc. (South San Francisco, Calif.), iOmx Therapeutics AG...
BioCentury | Sep 27, 2017
Financial News

Sofinnova names Richter managing partner

...Novo Holdings A/S (Hellerup, Denmark). She is also chairman of iOmx Therapeutics AG (Martinsried, Germany). Sofinnova co-led iOmx's...
...last year, marking the VC's entrance into immuno-oncology (see BioCentury, Sept. 26, 2016) . Elizabeth S. Eaton iOmx Therapeutics AG Novo...
BioCentury | May 25, 2017
Finance

Europe’s translational springtime

...Techology ; Francis Crick Institute ; King’s College London ; Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) iOmx Therapeutics AG...
...was cancer play iOmx Therapeutics AG , based on technology from the German Cancer Research Center (DKFZ). iOmx...
...et de la Recherche Médicale (INSERM), Paris, France The Institute of Cancer Research, London, U.K. iOmx Therapeutics AG...
BioCentury | Dec 9, 2016
Emerging Company Profile

Tumor cell checkpoints

...the activity of T cells?” The targets were identified using high throughput siRNA screening technology iOmx...
...iOmx plans to develop mAbs for patients who failed treatment with PD-1/PD-L1 inhibitors. Meier-Ewert said iOmx...
...paper describing iOmx’s technology, is “promising.” The 2015 paper, published in EMBO Molecular Medicine by iOmx’s...
BioCentury | Sep 26, 2016
Finance

Getting into the I-O mix

...After years of sitting on the sidelines, Sofinnova Partners is entering immuno-oncology by backing iOmx Therapeutics AG's €40...
...PD-L1 axis," said Sofinnova's Henrijette Richter, who is iOmx's chairman. "What captured us is that iOmx...
...financing is the fourth-largest German biotech series A since BioCentury started tracking financings in 1994. iOmx's...
BioCentury | Sep 26, 2016
Financial News

iOmx completes venture financing

iOmx Therapeutics AG , Martinsried, Germany Business: Cancer Date completed: 2016-09-22 Type: Venture financing Raised: EUR40 million ($44.6 million) Investors: MPM Capital; Sofinnova Partners; Wellington Partners; Merck Ventures B.V. WIR Staff...
BioCentury | Sep 22, 2016
Financial News

iOmx raises EUR 40M series A round

...Immuno-oncology company iOmx Therapeutics AG (Martinsried, Germany) raised EUR 40 million ($44.6 million) in a series A round...
...preclinical-stage biotech is developing antibodies against checkpoint targets found on tumors rather than immune cells. iOmx...
Items per page:
1 - 10 of 10